DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $355 | -30.1% | 17,200 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $508 | +56.3% | 17,200 | +22.0% | 0.00% | +50.0% |
| Q1 2023 | $325 | -17.1% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $392 | -99.9% | 14,100 | +5.2% | 0.00% | -33.3% |
| Q3 2022 | $411,000 | +4.3% | 13,400 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $394,000 | +3.7% | 13,400 | +13.6% | 0.00% | +50.0% |
| Q1 2022 | $380,000 | -52.7% | 11,800 | -34.4% | 0.00% | -50.0% |
| Q4 2021 | $803,000 | -11.6% | 18,000 | 0.0% | 0.00% | -20.0% |
| Q3 2021 | $908,000 | -35.7% | 18,000 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $1,412,000 | +35.9% | 18,000 | -1.1% | 0.01% | +16.7% |
| Q1 2021 | $1,039,000 | -12.0% | 18,200 | +29.1% | 0.01% | -14.3% |
| Q4 2020 | $1,181,000 | +133.9% | 14,100 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $505,000 | -26.0% | 14,100 | -50.0% | 0.00% | +33.3% |
| Q2 2020 | $682,000 | – | 28,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |